Smell and taste alterations in COVID-19: a cross-sectional analysis of different cohorts.
Age Factors
Betacoronavirus
COVID-19
Coronavirus Infections
/ epidemiology
Cross-Sectional Studies
Dysgeusia
/ diagnosis
Female
Humans
Italy
/ epidemiology
Male
Middle Aged
Olfaction Disorders
/ diagnosis
Pandemics
Pneumonia, Viral
/ epidemiology
Prevalence
Recovery of Function
SARS-CoV-2
Sex Factors
Smell
Symptom Assessment
/ methods
COVID-19
SARS-CoV-2
gustatory dysfunction
olfactory dysfunction
smell
taste
Journal
International forum of allergy & rhinology
ISSN: 2042-6984
Titre abrégé: Int Forum Allergy Rhinol
Pays: United States
ID NLM: 101550261
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
30
04
2020
revised:
08
05
2020
accepted:
11
05
2020
pubmed:
16
5
2020
medline:
13
8
2020
entrez:
16
5
2020
Statut:
ppublish
Résumé
Olfactory (OD) and gustatory (GD) dysfunction have been proven to be a typical symptom of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection. However, their prevalence in different patient populations still needs to be clarified. A cross-sectional study was performed from March 27 to April 1, 2020, in Northern Italy. Physicians administered a survey-based questionnaire to SARS-CoV-2-positive patients with the aim of assessing symptoms, focusing on OD and GD. Two groups were studied: group A, patients hospitalized at Azianda Socio Sanitaria Territoriale (ASST) Spedali Civili University Hospital of Brescia; and group B, home-quarantined subjects. A total of 508 patients were enrolled: 295 in group A and 213 in group B. Mean age ± standard deviation (SD) was 55 ± 15 years; 56% were men. Overall, OD and GD were present in 56% (95% confidence interval [CI], 51% to 60%) and 63% (95% CI, 59% to 67%) of cases, respectively. In group A, the prevalence of OD and GD was 44% (95% CI, 38% to 50%) and 52% (95% CI, 46% to 58%), respectively. In group B, the prevalence of OD and GD was 72% (95% CI, 65% to 79%) and 79% (95% CI, 73% to 84%), respectively. In the entire cohort, total loss of olfaction and taste was reported in 64% and 60% of cases, respectively. OD and GD occurred as the first symptom in 10% and 11% of cases, respectively; in the remaining cases, they occurred after a mean of 4 ± 3 days following the first symptom. At the time of the questionnaire, complete resolution of OD and GD was reported in 52% and 55% of cases, respectively (mean duration, 9 ± 5 days in both). OD and GD are more prevalent in home-quarantined subjects, and they are independently associated with younger age and female gender.
Sections du résumé
BACKGROUND
BACKGROUND
Olfactory (OD) and gustatory (GD) dysfunction have been proven to be a typical symptom of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection. However, their prevalence in different patient populations still needs to be clarified.
METHODS
METHODS
A cross-sectional study was performed from March 27 to April 1, 2020, in Northern Italy. Physicians administered a survey-based questionnaire to SARS-CoV-2-positive patients with the aim of assessing symptoms, focusing on OD and GD. Two groups were studied: group A, patients hospitalized at Azianda Socio Sanitaria Territoriale (ASST) Spedali Civili University Hospital of Brescia; and group B, home-quarantined subjects.
RESULTS
RESULTS
A total of 508 patients were enrolled: 295 in group A and 213 in group B. Mean age ± standard deviation (SD) was 55 ± 15 years; 56% were men. Overall, OD and GD were present in 56% (95% confidence interval [CI], 51% to 60%) and 63% (95% CI, 59% to 67%) of cases, respectively. In group A, the prevalence of OD and GD was 44% (95% CI, 38% to 50%) and 52% (95% CI, 46% to 58%), respectively. In group B, the prevalence of OD and GD was 72% (95% CI, 65% to 79%) and 79% (95% CI, 73% to 84%), respectively. In the entire cohort, total loss of olfaction and taste was reported in 64% and 60% of cases, respectively. OD and GD occurred as the first symptom in 10% and 11% of cases, respectively; in the remaining cases, they occurred after a mean of 4 ± 3 days following the first symptom. At the time of the questionnaire, complete resolution of OD and GD was reported in 52% and 55% of cases, respectively (mean duration, 9 ± 5 days in both).
CONCLUSION
CONCLUSIONS
OD and GD are more prevalent in home-quarantined subjects, and they are independently associated with younger age and female gender.
Identifiants
pubmed: 32410386
doi: 10.1002/alr.22610
pmc: PMC7272886
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
955-962Informations de copyright
© 2020 ARS-AAOA, LLC.
Références
Clin Infect Dis. 2020 Jul 28;71(15):889-890
pubmed: 32215618
Curr Allergy Asthma Rep. 2004 May;4(3):230-6
pubmed: 15056406
Acta Neurol Taiwan. 2006 Mar;15(1):26-8
pubmed: 16599281
Int Forum Allergy Rhinol. 2020 Aug;10(8):944-950
pubmed: 32301284
ACS Chem Neurosci. 2020 Apr 1;11(7):995-998
pubmed: 32167747
Science. 2020 May 1;368(6490):489-493
pubmed: 32179701
J Pathol. 2004 Jun;203(2):631-7
pubmed: 15141377
J Virol. 2018 Aug 16;92(17):
pubmed: 29925652
Int Forum Allergy Rhinol. 2020 Jul;10(7):806-813
pubmed: 32279441
Int Forum Allergy Rhinol. 2020 Aug;10(8):955-962
pubmed: 32410386
Radiology. 2020 Aug;296(2):E32-E40
pubmed: 32101510
J Med Virol. 2020 Jun;92(6):552-555
pubmed: 32104915
Science. 2003 Jun 20;300(5627):1966-70
pubmed: 12766207
Chem Senses. 2016 Jan;41(1):69-76
pubmed: 26487703
Lancet. 2020 Apr 11;395(10231):1189-1190
pubmed: 32224299
Arch Otolaryngol Head Neck Surg. 1991 May;117(5):519-28
pubmed: 2021470
J Virol. 2008 Aug;82(15):7264-75
pubmed: 18495771
Radiol Med. 2020 May;125(5):509-513
pubmed: 32358689
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261
pubmed: 32253535
Ann Otol Rhinol Laryngol. 2003 Nov;112(11):971-8
pubmed: 14653367
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
J Clin Epidemiol. 2008 Apr;61(4):344-9
pubmed: 18313558
Laryngoscope. 2007 Feb;117(2):272-7
pubmed: 17277621
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Int J Oral Sci. 2020 Feb 24;12(1):8
pubmed: 32094336
Radiol Cardiothorac Imaging. 2020 Mar 17;2(2):e200110
pubmed: 33778566
Int Forum Allergy Rhinol. 2020 Jul;10(7):821-831
pubmed: 32329222
Rhinol Suppl. 2017 Mar;54(26):1-30
pubmed: 29528615